The study will enroll 300 patients with mild to moderate psoriasis at 20 investigational centers across the US. The placebo- and active-controlled study will evaluate three concentrations of becocalcidiol administered once daily versus a vehicle and active control over a 12-week period.
Klaus Theobald, chief medical officer of CollaGenex, said: “We are encouraged by the results from an earlier Phase II trial that demonstrated a dose-response relationship for becocalcidiol in the treatment of psoriasis. The current trial is designed to further explore and optimize the treatment regimen.”